Singh Fiza, Weinberg Jeffrey M
Department of Dermatology, St Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA.
Cutis. 2005 Sep;76(3):186-8.
Rituximab, a human-mouse, chimeric, monoclonal antibody that targets the B-cell CD20 antigen and causes rapid and specific B-cell depletion, is indicated for the treatment of low-grade or follicular, relapsed or refractory, CD20+ B-cell, non-Hodgkin lymphoma (NHL). We report the case of a middle-aged woman with psoriasis who experienced a partial sustained remission of her psoriasis after treatment with rituximab for NHL and discuss potential pathophysiologic mechanisms for this unexpected effect in a condition known to be mediated by T cells.
利妥昔单抗是一种人鼠嵌合单克隆抗体，靶向B细胞CD20抗原，可迅速特异性清除B细胞，适用于治疗低度或滤泡性、复发或难治性、CD20+B细胞非霍奇金淋巴瘤（NHL）。我们报告了一例中年银屑病女性患者，在用利妥昔单抗治疗NHL后银屑病出现部分持续缓解，并讨论了在已知由T细胞介导的疾病中这种意外效果的潜在病理生理机制。
